375 related articles for article (PubMed ID: 16912889)
1. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
2. Optimal sampling and limited sampling strategies for estimation of unbound platinum AUC after nedaplatin infusion.
Ishibashi T; Fukumura K; Yano Y; Oguma T
Anticancer Res; 2005; 25(2B):1283-9. PubMed ID: 15865079
[TBL] [Abstract][Full Text] [Related]
3. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients.
Ishibashi T; Yano Y; Oguma T
Cancer Chemother Pharmacol; 2002 Sep; 50(3):230-6. PubMed ID: 12203105
[TBL] [Abstract][Full Text] [Related]
4. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
Yamamoto N; Tamura T; Kurata T; Yamamoto N; Sekine I; Kunitoh H; Ohe Y; Saijo N
Cancer Chemother Pharmacol; 2009 Dec; 65(1):79-88. PubMed ID: 19396598
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of concurrent chemoradiation with weekly nedaplatin in patients with squamous cell carcinoma of the uterine cervix.
Yoshinaga K; Niikura H; Ogawa Y; Nemoto K; Nagase S; Takano T; Ito K; Yaegashi N
Gynecol Oncol; 2007 Jan; 104(1):36-40. PubMed ID: 16889822
[TBL] [Abstract][Full Text] [Related]
6. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis.
Ishibashi T; Yano Y; Oguma T
Anticancer Res; 2005; 25(2B):1273-81. PubMed ID: 15865078
[TBL] [Abstract][Full Text] [Related]
7. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study for determination of the dosage formula for intra-arterial infusion chemotherapy with nedaplatin].
Ohbayashi Y; Miyake M; Iwasaki A; Ogawa T; Nagahata S; Toyama Y; Ohkawa M
Gan To Kagaku Ryoho; 2004 May; 31(5):713-6. PubMed ID: 15170978
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a formula for individual dosage of nedaplatin based on renal function.
Sato S; Fujiwara H; Oishi T; Shimada M; Machida S; Takei Y; Itamochi H; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2012 Mar; 69(3):599-603. PubMed ID: 21918903
[TBL] [Abstract][Full Text] [Related]
12. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
Oguri T; Shimokata T; Inada M; Ito I; Ando Y; Sasaki Y; Hasegawa Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):813-7. PubMed ID: 20563583
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study of the area under the blood concentration-time curve of targeting intra-arterial infusion chemotherapy with nedaplatin for primary oral cancer].
Ohbayashi Y; Miyake M; Iwasaki A; Ogawa T; Nagahata S; Toyama Y; Ohkawa M
Gan To Kagaku Ryoho; 2004 Jan; 31(1):41-4. PubMed ID: 14750319
[TBL] [Abstract][Full Text] [Related]
17. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
[TBL] [Abstract][Full Text] [Related]
18. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
19. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; van Hoek B
Aliment Pharmacol Ther; 2005 Mar; 21(5):549-57. PubMed ID: 15740538
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
